Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04486833
Title TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone (Acclaim-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.

lung non-small cell carcinoma


Osimertinib + Quaratusugene Ozeplasmid


Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Valkyrie Clinical Trials Recruiting Los Angeles California 90067 United States Details
Rocky Mountain Cancer Centers Recruiting Lone Tree Colorado 80124 United States Details
Maryland Oncology Hematology Recruiting Rockville Maryland 20850 United States Details
Millennium Oncology Recruiting Houston Texas 77090 United States Details
Virginia Cancer Specialists Recruiting Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from for the field